ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $125,266 | -62.4% | 18,287 | -43.1% | 0.00% | – |
| Q2 2023 | $333,571 | +140.0% | 32,167 | +87.2% | 0.00% | – |
| Q1 2023 | $139,002 | +16.3% | 17,182 | +126.5% | 0.00% | – |
| Q4 2022 | $119,480 | +23.2% | 7,586 | +24.2% | 0.00% | – |
| Q3 2022 | $97,000 | +9.0% | 6,110 | -3.4% | 0.00% | – |
| Q2 2022 | $89,000 | -87.0% | 6,327 | -84.1% | 0.00% | – |
| Q1 2022 | $686,000 | +43.8% | 39,811 | +21.4% | 0.00% | – |
| Q4 2021 | $477,000 | -78.0% | 32,798 | -72.8% | 0.00% | – |
| Q3 2021 | $2,170,000 | +10750.0% | 120,549 | +10750.5% | 0.00% | – |
| Q2 2021 | $20,000 | -42.9% | 1,111 | -20.1% | 0.00% | – |
| Q1 2021 | $35,000 | -83.6% | 1,390 | -95.8% | 0.00% | – |
| Q4 2020 | $213,000 | +5225.0% | 32,936 | +2606.3% | 0.00% | – |
| Q3 2020 | $4,000 | +33.3% | 1,217 | -45.6% | 0.00% | – |
| Q2 2020 | $3,000 | -94.4% | 2,236 | -95.7% | 0.00% | – |
| Q1 2020 | $54,000 | +10.2% | 52,350 | +100.3% | 0.00% | – |
| Q4 2019 | $49,000 | +44.1% | 26,137 | -18.4% | 0.00% | – |
| Q3 2019 | $34,000 | -37.0% | 32,013 | +28.2% | 0.00% | – |
| Q2 2019 | $54,000 | -70.7% | 24,966 | -18.3% | 0.00% | – |
| Q1 2019 | $184,000 | -8.5% | 30,562 | +12.2% | 0.00% | – |
| Q4 2018 | $201,000 | -12.2% | 27,233 | +73.1% | 0.00% | – |
| Q3 2018 | $229,000 | -22.9% | 15,735 | +5.7% | 0.00% | – |
| Q2 2018 | $297,000 | +10.4% | 14,881 | -2.8% | 0.00% | – |
| Q1 2018 | $269,000 | -28.5% | 15,314 | +0.6% | 0.00% | – |
| Q4 2017 | $376,000 | -65.2% | 15,227 | -63.6% | 0.00% | – |
| Q3 2017 | $1,079,000 | -2.7% | 41,804 | +2.3% | 0.00% | – |
| Q2 2017 | $1,109,000 | +200.5% | 40,883 | +230.8% | 0.00% | – |
| Q1 2017 | $369,000 | +110.9% | 12,359 | +91.3% | 0.00% | – |
| Q4 2016 | $175,000 | +108.3% | 6,459 | +97.8% | 0.00% | – |
| Q3 2016 | $84,000 | +180.0% | 3,266 | +98.1% | 0.00% | – |
| Q2 2016 | $30,000 | 0.0% | 1,649 | -11.2% | 0.00% | – |
| Q1 2016 | $30,000 | -33.3% | 1,858 | +11.9% | 0.00% | – |
| Q4 2015 | $45,000 | – | 1,660 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |